Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Nat Neurosci. 2019 Jan 28;22(3):353–361. doi: 10.1038/s41593-018-0320-0

Figure 2.

Figure 2.

Cross-diagnosis genome-wide association study results. (A) Manhattan plot depicting −log10 of two-tailed p-values from case-control logistic regression association tests at 8,018,013 imputed SNP dosages in 46,008 cases and 19,526 controls identifies four genome-wide significant loci (green) and 46 suggestive loci (gold, orange). (B) QQ-plot comparing the distribution of -log10 association p-values to that expected under the global null hypothesis. For each genome-wide significant locus, 1 (C), 2 (D), 3 (E), and 4 (F), ordered as in the Manhattan plot, the odds ratio (OR) and approximate 95% confidence interval (CI) for the SNP from the XDX GWAS (green) is similar in sign and magnitude to ORs from associations with single indication case groups (blue). Sample sizes for single indication GWAS cohorts described in Supplementary Table 1 and full association statistics in Supplementary Tables 1011. sFDR, stratified false discovery rate; MAF, minor allele frequency; Dx, diagnosis; XDX, cross-diagnosis; ADHD, attention-deficit, hyperactivity disorder; AFF, affective disorder; ANO, anorexia; ASD, autism-spectrum disorder; BIP, bipolar disorder; SCZ, schizophrenia; OTH, other indications not falling within individual disorder categories.